News
MNKKQ
--
0.00%
--
BRIEF-Mallinckrodt Presents Results From Two Retrospective Studies On HRS-1 Patients
reuters.com · 11/12 14:09
Mallinckrodt Presents Results from Two Retrospective Studies on Real World Characteristics and Outcomes of Patients with Hepatorenal Syndrome Type-1 (HRS-1) at The Liver Meeting Digital Experience
Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced findings from two retrospective medical chart review studies on real world outcomes of patients hospitalized with hepatorenal syndrome type-1 (HRS-1) treated with terlip...
PR Newswire · 11/12 13:00
BRIEF-Mallinckrodt PLC Says For Quarter Ended Sept. 24, Net Sales Were $507.2 Mln And Loss Per Share Was $3.11
reuters.com · 11/02 11:54
BRIEF-The Buxton Helmsley Group Issued Open Letter To SEC Regarding Mallinckrodt
reuters.com · 10/26 17:02
Mallinckrodt Presents Results on Real World Treatment Patterns and Outcomes in Hospitalized Patients with Esophageal Variceal Hemorrhage and Liver Cirrhosis Treated with Terlipressin at the American College of Gastroenterology Annual Scientific Meeting
Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced results from a retrospective medical chart review study examining treatment patterns and outcomes in hospitalized patients with esophageal variceal hemorrhage (EVH) and ...
PR Newswire · 10/25 10:45
U.S. Supreme Court rejects challenge to New York tax on opioid companies
reuters.com · 10/04 13:33
Mallinckrodt Reaches Settlement Agreement With More Creditors
marketwatch.com · 09/03 10:54
BRIEF-Mallinckrodt Reaches Settlements With The Official Committee Of Opioid Related Creditors, The Official Committee Of Unsecured Creditors And Second Lien Noteholders
reuters.com · 09/03 10:37
Mallinckrodt Reaches Settlements with the Official Committee of Opioid Related Creditors, the Official Committee of Unsecured Creditors and Second Lien Noteholders
Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that it has reached an agreement with the Official Committee of Opioid Related Creditors (the "OCC") and the Restructuring Support Agreement (the "RSA") Parties to support ...
PR Newswire · 09/03 10:16
UPDATE 1-Drugmaker Endo settles opioid claims by Tennessee counties, cities for $35 mln
reuters.com · 07/22 17:10
UPDATE 6-U.S. state officials urge support for landmark $26 bln opioid settlement
reuters.com · 07/21 18:16
Drugmakers, pharmacies next targets for U.S. opioid settlements
reuters.com · 07/21 10:00
UPDATE 1-U.S. states to unveil $26 billion opioid settlement with drug distributors, J&J this week - source
reuters.com · 07/19 23:43
Mallinckrodt's Phase 3 STRATA2016 study results published in peer-reviewed journal
Mallinckrodt (MNKKQ) announces publication of results from Phase 3 STRATA2016 trial of StrataGraft in a peer-reviewed journal, Burns.The trial, which evaluated the efficacy and safety of a single application of StrataGraft
Seekingalpha · 07/07 11:22
BRIEF-Mallinckrodt Announces Publication Of Phase 3 Strata2016 Study In Burns
reuters.com · 07/07 10:48
Mallinckrodt Announces Publication of Phase 3 STRATA2016 Study in Burns
Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced publication of results from the pivotal Phase 3 STRATA2016 clinical trial of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – ...
PR Newswire · 07/07 10:45
BRIEF-Mallinckrodt Announces Inclusion Of Acthar Gel In New European Respiratory Society Treatment Guidelines For Patients With Pulmonary Sarcoidosis
reuters.com · 07/01 12:01
Mallinckrodt Wins FDA Approval For Its Regenerative Skin Burn Graft
Benzinga · 06/16 13:21
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15)
Benzinga · 06/16 12:20
Mallinckrodt Announces U.S. FDA Approval of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat)
Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat) for the t...
PR Newswire · 06/15 23:15
Webull provides a variety of real-time MNKKQ stock news. You can receive the latest news about Mallinckrodt Plc through multiple platforms. This information may help you make smarter investment decisions.
About MNKKQ
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.